Studio nicolucci EN
6 months of treatment with Gdue favorly affect
all components of Metabolic Syndrome
This is demonstrated by a major new real-life study* over 505 patients
* "Effectiveness of Ascophyllum nodosum and Fucus vesiculosus on Metabolic Syndrome Components: A Real-World, Observational Study"
Journal of Diabetes Research – September 2021 - Antonio Nicolucci, Maria Chiara Rossi e Massimiliano Petrelli
DISCOVER THE RESULT OF THE STUDY
previous arrow
next arrow

THE EFFECTIVE NUTRACEUTICAL ALLY

A DECISIVE SUPPORT FOR PEOPLE SUFFERING FROM OVERWEIGHT, OBESITY, DYSGLYCAEMIA, DIABETES AND CARDIOVASCULAR RISK (METABOLIC SYNDROME)

THE EFFECTIVE NUTRACEUTICAL ALLY

A DECISIVE SUPPORT FOR PEOPLE SUFFERING FROM OVERWEIGHT, OBESITY, DYSGLYCAEMIA, DIABETES AND CARDIOVASCULAR RISK (METABOLIC SYNDROME)

THE EFFECTIVE NUTRACEUTICAL ALLY

A DECISIVE SUPPORT FOR PEOPLE SUFFERING FROM OVERWEIGHT, OBESITY, DYSGLYCAEMIA, DIABETES AND CARDIOVASCULAR RISK (METABOLIC SYNDROME)

What is Gdue?

Gdue is a nutraceutical product containing a phytocomplex extracted from Ascophyllum Nodosum and Fucus Vesiculosus titrated at 20% polyphenols and Chromium Picolinate.

Thanks to Chromium and Ascophyllum Nodosum and Fucus Vesiculosus, Gdue contributes to maintaining normal blood sugar levels and balancing body weight.

1 CAPSULE BEFORE MAIN MEALS
(2/3 CAPSULES/DAY)
REDUCES POSTPRANDIAL BLOOD GLUCOSE
DOES NOT INDUCE HYPOGLYCAEMIA
NO SIDE EFFECTS
GLUTEN FREE

What is Gdue?

Gdue is a nutraceutical product containing a phytocomplex extracted from Ascophyllum Nodosum and Fucus Vesiculosus titrated at 20% polyphenols and Chromium Picolinate.

Thanks to Chromium and Ascophyllum Nodosum and Fucus Vesiculosus, Gdue contributes to maintaining normal blood sugar levels and balancing body weight.

  • REDUCES POSTPRANDIAL BLOOD GLUCOSE

  • DOES NOT INDUCE HYPOGLYCAEMIA

  • NO SIDE EFFECTS

  • GLUTEN FREE

1 CAPSULA PRIMA DEI PASTI PRINCIPALI

(2/3 CAPSULE/DIE)

High postprandial blood glucose level is the first sign that physiological control mechanisms are beginning to be altered and, thus, the first step towards:

  • ALTERATION OF THE VARIOUS CONDITIONS OF THE METABOLIC SYNDROME
    (weight, hypertension, hypercholesterolemia, hypertriglyceridemia, insulin resistance)

  • INCREASED CARDIOVASCULAR RISK
  • DIABETES AND ITS COMPLICATIONS

High postprandial blood glucose level is the first sign that physiological control mechanisms are beginning to be altered and, thus, the first step towards:

– ALTERATION OF THE VARIOUS CONDITIONS OF THE METABOLIC SYNDROME
(weight, hypertension, hypercholesterolemia, hypertriglyceridemia, insulin resistance)

– INCREASED CARDIOVASCULAR RISK

– DIABETES AND ITS COMPLICATIONS

Why is Gdue your effective ally

DIET

  • It reduces the rate of carbohydrate absorbed in the intestines
  • Reduces the glycaemic index of food taken
  • Ensures a slower absorption of starches and sugars
  • Reduces postprandial glycaemic peaks
  • Reduces the resulting insulin response
  • Increases the sense of satiety

TREATMENT

  • Does not induce hypoglycaemia
  • ‘Upstream’ support of hypoglycaemic treatment
  • Does not have side effects typical of other α-glucosidase inhibitors

PHYSICAL ACTIVITY

  • By prolonging carbohydrate absorption, it predisposes to a constant supply of carbohydrates, leading to prolonged energy availability
  • Since it does not cause hypoglycaemia, there is no fatigue, and predisposes to better and more intense physical activity

It is a key dietary support for people suffering from overweight, obesity, dysglycaemia, diabetes and cardiovascular risk

REDUCES THE RATE OF CARBOHYDRATE ABSORPTION

THE ENZYME INHIBITION OF GDUE REDUCES THE RATE OF CARBOHYDRATE ABSORPTION, MAKING CARBOHYDRATES AVAILABLE FOR SEVERAL HOURS

REDUCES INSULIN SECRETION

RESULTING IN AN ENHANCED OVERALL PHYSIOLOGICAL METABOLIC RESPONSE

INCREASED SENSE OF SATIETY

AS IT REDUCES PEAKS OF POSTPRANDIAL BLOOD GLUCOSE LEVEL

DIET

  • It reduces the rate of carbohydrate absorbed in the intestines
  • Reduces the glycaemic index of food taken
  • Ensures a slower absorption of starches and sugars
  • Reduces postprandial glycaemic peaks
  • Reduces the resulting insulin response
  • Increases the sense of satiety

TREATMENT

  • Does not induce hypoglycaemia
  • ‘Upstream’ support of hypoglycaemic treatment
  • Does not have side effects typical of other α-glucosidase inhibitors

PHYSICAL ACTIVITY

  • By prolonging carbohydrate absorption, it predisposes to a constant supply of carbohydrates, leading to prolonged energy availability
  • Since it does not cause hypoglycaemia, there is no fatigue, and predisposes to better and more intense physical activity

REDUCES THE RATE OF CARBOHYDRATE ABSORPTION

THE ENZYME INHIBITION OF GDUE REDUCES THE RATE OF CARBOHYDRATE ABSORPTION, MAKING CARBOHYDRATES AVAILABLE FOR SEVERAL HOURS

REDUCES INSULIN SECRETION

RESULTING IN AN ENHANCED OVERALL PHYSIOLOGICAL METABOLIC RESPONSE

INCREASED SENSE OF SATIETY

AS IT REDUCES PEAKS OF POSTPRANDIAL BLOOD GLUCOSE LEVEL

Scientific Publications

A MAJOR NEW REAL-LIFE STUDY* OVER 505 SUBJECTS HAS SHOWN THAT 6 MONTHS OF TREATMENT WITH GDUE HAS A FAVOURABLE IMPACT ON ALL THE CONDITIONS OF THE METABOLIC SYNDROME.

*”Effectiveness of Ascophyllum nodosum and Fucus vesiculosus on Metabolic Syndrome Components: A Real-World, Observational Study” • Antonio Nicolucci, Maria Chiara Rossi e Massimiliano Petrelli
Journal of Diabetes Research – September 2021

Reduction of Cardiovascular Risk by 27.7%

due to action on the following parameters:

  • -7.3Kg
    WEIGHT REDUCTION
  • -7.5cm
    WAIST CIRCUMFERENCE REDUCTION
  • -0,55%
    HbA1c REDUCTION
  • -16,3 mg/dL
    FASTING BLOOD SUGAR REDUCTION
  • -18,2 mg/dL
    LDL REDUCTION
  • +2,9 mg/dL
    HDL INCREASE
  • -39 mg/dL
    TRIGLYCERIDES REDUCTION
  • -7,1 mmHg
    SYSTOLIC BLOOD PRESSURE REDUCTION
  • -4,2 mmHg
    DIASTOLIC BLOOD PRESSURE REDUCTION
Reduction of Cardiovascular Risk by 27.7%

due to action on the following parameters:

  • -7.3Kg WEIGHT REDUCTION
  • -7.5cm WAIST CIRCUMFERENCE REDUCTION
  • -0,55% HbA1c REDUCTION
  • -16,3 mg/dL FASTING BLOOD SUGAR REDUCTION
  • -18,2 mg/dL LDL REDUCTION
  • +2,9 mg/dL HDL INCREASE
  • -39 mg/dL TRIGLYCERIDES REDUCTION

  • -7,1 mmHg SYSTOLIC BLOOD PRESSURE REDUCTION

  • -4,2 mmHg DIASTOLIC BLOOD PRESSURE REDUCTION

News